Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Available  
  • Page 1 ·  Next »

NCT ID: NCT05235347 Available - Covid19 Clinical Trials

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

An expanded access program for sotrovimab administered intravenously to participants with COVID-19 illness who meet current authorized/approved criteria for use of sotrovimab.

NCT ID: NCT05157165 Available - COVID-19 Clinical Trials

Convalescent Plasma in Hospitalized COVID-19 Patients

Start date: n/a
Phase:
Study type: Expanded Access

The study assesses the efficacy and safety of administration of hyperimmune plasma in hospitalized COVID-19 patients. Efficacy was measured as 28-day mortality following convalescent plasma transfusion. Safety was measured as the rate of adverse reactions. to plasma infusion.

NCT ID: NCT04798066 Available - Parkinson Disease Clinical Trials

HBPCOV01:"Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome" HBPD05: "Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease"

Start date: n/a
Phase:
Study type: Expanded Access

IND 019680 - HBPCOVID01 This is an Intermediate- Size Patient Population Expanded Access Protocol to evaluate the safety and efficacy of HB-adMSCs for the treatment of patients with Post-COVID-19 Syndrome. The investigational product will be an add-on treatment to the standard of care. IND 027966 - HBPD05 This is an Intermediate Size Patient Population Expanded Access IND to Evaluate the Safety of autologous HB-adMSCs for the treatment of patients with Parkinson's disease.

NCT ID: NCT04657458 Available - Covid19 Clinical Trials

A Global Expanded Access Protocol on Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Infusion Treatment for Patients With COVID-19 Associated ARDS

Start date: n/a
Phase:
Study type: Expanded Access

Infusion Treatment Using Bone Marrow Mesenchymal Stem Cell (bmMSC) Derived Extracellular Vesicle Product, ExoFlo™, for COVID-19 Associated ARDS (EXIT COVID-19), is currently being studied in Protocol DB-EF-PhaseII-001 in patients with COVID-19 associated moderate to severe Acute Respiratory Distress Syndrome (ARDS). This expanded access protocol is an open-label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase II randomized controlled trial because they: - Do not meet phase II eligibility criteria at current phase II sites. - Do meet phase II eligibility criteria but cannot access phase II sites. - Do not meet phase II eligibility criteria & cannot access phase II sites. •

NCT ID: NCT04657406 Available - Covid19 Clinical Trials

Expanded Access to Zofin for Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

NCT ID: NCT04646031 Available - Covid19 Clinical Trials

Expanded Access to T89 for Treatment Use in Intermediate-size Patients Population With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access use program will provide a botanical drug of T89 for treatment use in an intermediate-size population infected with SARS-CoV-2 who have severe COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening condition.

NCT ID: NCT04617535 Available - COVID-19 Clinical Trials

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

NCT ID: NCT04472572 Available - COVID-19 Clinical Trials

Expanded Access to Convalescent Plasma for Treatment of COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access program will provide access to investigational convalescent plasma for patients at Hackensack University Medical Center infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.

NCT ID: NCT04456439 Available - Clinical trials for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.

NCT ID: NCT04453839 Available - Clinical trials for Critical COVID-19 With Respiratory Failure

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)

SAMICARE
Start date: n/a
Phase:
Study type: Expanded Access

Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor. Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization. Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download